Cortes-Perez Naima G, Ah-Leung Sandrine, Bermúdez-Humarán Luis G, Corthier Gérard, Wal Jean-Michel, Langella Philippe, Adel-Patient Karine
Laboratoire INRA d'Immuno-Allergie Alimentaire, DSV/SPI-Bâtiment 136, CEA de Saclay, 91191 Gif-sur-Yvette cedex, France.
Clin Vaccine Immunol. 2007 Mar;14(3):226-33. doi: 10.1128/CVI.00299-06. Epub 2007 Jan 3.
The Th1/Th2 balance deregulation toward a Th2 immune response plays a central role in allergy. We previously demonstrated that administration of recombinant Lactococcus lactis strains expressing bovine beta-lactoglobulin (BLG), a major cow's milk allergen, partially prevents mice from sensitization. In the present study, we aimed to improve this preventive effect by coadministration of L. lactis BLG and a second recombinant L. lactis strain producing biologically active interleukin-12 (IL-12). This L. lactis strain producing IL-12 was previously used to enhance the Th1 immune response in a tumoral murine model (L. G. Bermúdez-Humarán et al., J. Immunol. 175:7297-7302, 2005). A comparison of the administration of either BLG alone or BLG in the presence of IL-12 was conducted. A BLG-specific primary Th1 immune response was observed only after intranasal coadministration of both L. lactis BLG and IL-12-producing L. lactis, as demonstrated by the induction of serum-specific immunoglobulin G2a (IgG2a) concomitant with gamma interferon secretion by splenocytes, confirming the adjuvanticity of IL-12-producing L. lactis. Immunized mice were further sensitized by intraperitoneal administration of purified BLG, and the allergic reaction was elicited by intranasal challenge with purified BLG. Mice pretreated with BLG in either the presence or the absence of IL-12 were rendered completely tolerant to further allergic sensitization and elicitation. Pretreatment with either L. lactis BLG or L. lactis BLG and IL-12-producing L. lactis induces specific anti-BLG IgG2a production in serum and bronchoalveolar lavage (BAL) fluid. Although specific serum IgE was not affected by these pretreatments, the levels of eosinophilia and IL-5 secretion in BAL fluid were significantly reduced after BLG challenge in the groups pretreated with L. lactis BLG and L. lactis BLG-IL-12-producing L. lactis, demonstrating a decreased allergic reaction. Our data demonstrate for the first time (i) the induction of a protective Th1 response by the association of L. lactis BLG and IL-12-producing L. lactis which inhibits the elicitation of the allergic reaction to BLG in mice and (ii) the efficiency of intranasal administration of BLG for the induction of tolerance.
Th1/Th2平衡失调向Th2免疫反应方向发展在过敏反应中起核心作用。我们之前证明,给予表达牛β-乳球蛋白(BLG,一种主要的牛奶过敏原)的重组乳酸乳球菌菌株,可部分预防小鼠致敏。在本研究中,我们旨在通过联合给予乳酸乳球菌BLG和另一种产生生物活性白细胞介素-12(IL-12)的重组乳酸乳球菌菌株来提高这种预防效果。这种产生IL-12的乳酸乳球菌菌株之前曾用于增强肿瘤小鼠模型中的Th1免疫反应(L.G. Bermúdez-Humarán等人,《免疫学杂志》175:7297 - 7302,2005年)。我们对单独给予BLG或在IL-12存在下给予BLG进行了比较。仅在鼻腔联合给予乳酸乳球菌BLG和产生IL-12的乳酸乳球菌后,观察到了针对BLG的原发性Th1免疫反应,这表现为血清特异性免疫球蛋白G2a(IgG2a)的诱导以及脾细胞分泌γ干扰素,证实了产生IL-12的乳酸乳球菌的佐剂活性。通过腹腔注射纯化的BLG使免疫后的小鼠进一步致敏,并用纯化的BLG进行鼻腔激发以引发过敏反应。在有或无IL-12存在的情况下用BLG预处理的小鼠对进一步的过敏致敏和激发完全耐受。用乳酸乳球菌BLG或乳酸乳球菌BLG与产生IL-12的乳酸乳球菌预处理均可诱导血清和支气管肺泡灌洗(BAL)液中产生特异性抗BLG IgG2a。尽管这些预处理对特异性血清IgE没有影响,但在用乳酸乳球菌BLG和产生IL-12的乳酸乳球菌 - 乳酸乳球菌BLG预处理的组中,在BLG激发后,BAL液中的嗜酸性粒细胞增多和IL-5分泌水平显著降低,表明过敏反应减弱。我们的数据首次证明:(i)乳酸乳球菌BLG与产生IL-12的乳酸乳球菌联合可诱导保护性Th1反应,该反应可抑制小鼠对BLG的过敏反应激发;(ii)鼻腔给予BLG诱导耐受性的有效性。